Tromsø, Norway, 21[th] September 2023 - ArcticZymes Technologies ASA (OSE:AZT)
announces that Salt Active Nuclease High Quality GMP grade (SAN HQ GMP) has
passed the DMF filing Type II with the US Food and Drug Administration (FDA) and
has received the acknowledgement letter with the Master File number 29754 as a
reference.
This means that ArcticZymes can provide its customers with a Letter of
Authorization (LoA) for their product registrations with the US FDA upon
request. AZT anticipates commercial launch of SAN HQ GMP in Q4 2023.
For more information, please contact:
ArcticZymes Technologies
Chairman of the Board, Marie Roskrow Tel: +44 (0) 7496 959 743
marie.roskrow@arcticzymes.com
CEO, Michael Akoh Tel: +46 70 262 3715
michael.akoh@arcticymes.com
About ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.
The company is listed on the Oslo Stock Exchange since 2005 as ArcticZymes
Technologies under the [AZT] ticker. Its headquarters are based in Tromsø,
Norway, at the SIVA Innovation Centre.
ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents. For more information, please visit the website:
www.arcticzymes.com